Protalix is a leading brand dedicated to bringing recombinant therapeutic proteins to the market. They specialize in producing these proteins with their proprietary ProCellEx® plant cell-based expression system. This innovative technology allows them to create proteins with clinically improved profiles, providing better therapeutic outcomes for patients.

Protalix offers a wide range of plant-based proteins with enhanced therapeutic potential. One of their notable products in development is pegunigalsidase alfa (PRX-102), currently in Phase III for the treatment of Fabry disease. They also have alidornase alfa (PRX-110) in development for inhaled indications in respiratory diseases.

The brand takes pride in completing enrollment for all their clinical studies, showcasing their commitment to advancing medical research and development. Protalix actively seeks collaborations for their existing pipeline and the development of new therapeutic proteins. For more information about Protalix's innovative ProCellEx® platform and their cutting-edge pipeline, visit their website.

Collaborate with Protalix to contribute to the future of recombinant protein therapeutics